Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II preoperative cisplatin + docetaxel chemoradiotherapy followed by surgery for operable stage IIIA/IIIB non-small cell lung cancer
2009-015120-28Phase 2Active
- Sponsor
- Centre Antoine Lacassagne
- Start
- Oct 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Centre Antoine Lacassagne. Primary endpoints: Complete resection rate after induction treatment and Treatment-scheme mortality at 3 months. Started Oct 2009; status: active.
02
Drugs
cisplatindocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-015120-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015120-28.